

NOTE: The ABO/Rh type of the patient's red blood cells must be determined by an appropriate test procedure. Tests on each sample must include forward and reverse grouping. Discrepancies between cell and serum groups must be resolved before ABO group is assigned.

Evidence of Compliance:

- ✓ Logs or computer records with forward and reverse grouping

HSC.29901	A1 Red Cell Subgrouping	Phase II
-----------	-------------------------	----------



There is evidence of the specificity of A1 subgroup testing in the ABO system to distinguish A1 from other red cell subgroups.

NOTE: If the organ donor has been transfused with red blood cells in the past three months, ABO subgroup typing must be performed on a pretransfusion sample. This is due to the possibility of misinterpretation of ABO subgroup typing.

HSC.29909	Antisera/Reagent Red Cell QC	Phase II
-----------	------------------------------	----------



There are records of acceptable reactivity and specificity of typing sera and reagent red cells on each day of use, including a check against known positive and negative cells or antisera, or manufacturer's instructions for daily quality control are followed.

NOTE: Unless manufacturer's instructions state otherwise, the following apply:

- Typing reagents, including antisera (eg, anti-D, anti-K, anti-Fy(a)) and reagent red cells must be checked for reactivity and specificity on each day of use. Typing antisera must be checked with known positive and negative cells; reagent red cells must be checked with known positive and negative antisera.
- Each cell used for antibody screening must be checked each day of use for reactivity of at least one antigen using antisera of 1+ or greater avidity.
- Anti-IgG reactivity of antiglobulin reagents may be checked during antibody screening and crossmatching.

This checklist requirement can be satisfied by testing one vial of each reagent lot each day of testing.

REFERENCES

- 1) Department of Health and Human Services, Centers for Medicare and Medicaid Services. Clinical laboratory improvement amendments of 1988; final rule. *Fed Register*. 1992(Feb 28):7171 [42CFR493.1256]

HSC.29925	Historical Record Check - Red Cell Typing	Phase II
-----------	---	----------



ABO, Rh, and antibody screen test results are compared with results of the same tests performed previously to detect discrepancies.

Evidence of Compliance:

- ✓ Records of historical result comparisons

HSC.29941	Results Reporting - ABO Antibody Titers	Phase I
-----------	---	---------



The laboratory defines how to perform and interpret ABO antibody titers.

HSC.29949	Anti-D Controls	Phase II
-----------	-----------------	----------



Appropriate control(s) are used for anti-D testing.

NOTE: If an anti-D reagent contains a potentiating diluent, the appropriate control is the diluent alone. Controls used must be consistent with the manufacturer's instructions.